Covid 19
Conditions
Keywords
Covid-19, Renin Angiotensin Aldosterone System, Hormon disorders
Brief summary
As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course. Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described. Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease. In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.
Interventions
None listed
Sponsors
University Hospital, Montpellier
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Patients with Covid-19 diagnosis and hospitalized in our clinic
Exclusion criteria
\- Minor patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma aldosterone levels | 1 day (at inclusion) | Plasma aldosterone levels |
| Plasma renin levels | 1 day (at inclusion) | Plasma renin levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma aldosterone level | 1 day (at the end of hospitalization) | Plasma aldosterone level |
| Plasma ACTH level | 1 day (at the end of hospitalization) | Plasma ACTH level |
| Plasma cortisol level | 1 day (at inclusion) | Plasma cortisol level |
| Plasma T3l level | 1 day (at the end of hospitalization) | Plasma T3l level |
| Plasma LH level | 1 day (at inclusion) | Plasma LH level |
| covid-19 infection severity | 1 day (at inclusion) | covid-19 infection severity : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death). |
| Plasma estradiol (female) or testosterone (male) level | 1 day (at the end of hospitalization) | Plasma estradiol (female) or testosterone (male) level |
| Plasma FSH level | 1 day (at the end of hospitalization) | Plasma FSH level |
| type of treatments | 1 day | type of treatments |
| Clinical characteristics | 1 day | Clinical characteristics extracted from electronic medical |
| radiological characteristics | 1 day | radiological characteristics : quantification of the percentage of lesional damage to the pulmonary parenchyma |
| Plasma DHEA level | 1 day (at the end of hospitalization) | Plasma DHEA level |
| Maximum severity of Covid-19 infection | 1 day (at inclusion) | Maximum severity of Covid-19 infection using a seven-category ordinal scale at at the end of hospitalization : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death). |
Countries
France
Outcome results
None listed